157 related articles for article (PubMed ID: 2513643)
21. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations.
Lamberts R; Creutzfeldt W; Stöckmann F; Jacubaschke U; Maas S; Brunner G
Digestion; 1988; 39(2):126-35. PubMed ID: 3410169
[TBL] [Abstract][Full Text] [Related]
22. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Hage E; Hendel L; Gustafsen J; Hendel J
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
[TBL] [Abstract][Full Text] [Related]
23. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis.
Solcia E; Fiocca R; Villani L; Luinetti O; Capella C
Am J Surg Pathol; 1995; 19 Suppl 1():S1-7. PubMed ID: 7762735
[TBL] [Abstract][Full Text] [Related]
24. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during long-term acid-suppressive treatment in Japan.
Uemura N; Okamoto S; Yamamoto S; Matsumura N; Yamaguchi S; Mashiba H; Sasaki N; Taniyama K
Aliment Pharmacol Ther; 2000 Oct; 14(10):1345-52. PubMed ID: 11012481
[TBL] [Abstract][Full Text] [Related]
25. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells.
Maton PN; Lack EE; Collen MJ; Cornelius MJ; David E; Gardner JD; Jensen RT
Gastroenterology; 1990 Oct; 99(4):943-50. PubMed ID: 1697548
[TBL] [Abstract][Full Text] [Related]
26. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine.
Lundell L; Backman L; Ekström P; Enander LK; Falkmer S; Fausa O; Grimelius L; Havu N; Lind T; Lönroth H
Scand J Gastroenterol; 1991 Mar; 26(3):248-56. PubMed ID: 1853146
[TBL] [Abstract][Full Text] [Related]
27. Medical therapy of patients with reflux oesophagitis poorly responsive to H2-receptor antagonist therapy.
Klinkenberg-Knol EC; Meuwissen SG
Digestion; 1992; 51 Suppl 1():44-8. PubMed ID: 1356868
[TBL] [Abstract][Full Text] [Related]
28. Clinical development programme for omeprazole.
Walan A
Digestion; 1990; 47 Suppl 1():54-8; discussion 76. PubMed ID: 2093016
[TBL] [Abstract][Full Text] [Related]
29. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine.
Brunner G; Creutzfeldt W
Scand J Gastroenterol Suppl; 1989; 166():101-5; discussion 111-3. PubMed ID: 2513641
[TBL] [Abstract][Full Text] [Related]
30. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.
Lamberts R; Creutzfeldt W; Strüber HG; Brunner G; Solcia E
Gastroenterology; 1993 May; 104(5):1356-70. PubMed ID: 8482449
[TBL] [Abstract][Full Text] [Related]
31. Are enterochromaffinlike cell tumours reversible? An experimental study on gastric carcinoids induced in Mastomys by histamine2-receptor blockade.
Wängberg B; Nilsson O; Theodorsson E; Modlin IM; Dahlström A; Ahlman H
Regul Pept; 1995 Mar; 56(1):19-33. PubMed ID: 7770630
[TBL] [Abstract][Full Text] [Related]
32. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
McTavish D; Buckley MM; Heel RC
Drugs; 1991 Jul; 42(1):138-70. PubMed ID: 1718683
[TBL] [Abstract][Full Text] [Related]
33. Eradication therapy of Helicobacter pylori directly induces apoptosis in inflammation-related immunocytes in the gastric mucosa--possible mechanism for cure of peptic ulcer disease and MALT lymphoma with a low-grade malignancy.
Ohara T; Kanoh Y; Higuchi K; Arakawa T; Morisita T
Hepatogastroenterology; 2003; 50(51):607-9. PubMed ID: 12828043
[TBL] [Abstract][Full Text] [Related]
34. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Barradell LB; Faulds D; McTavish D
Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017
[TBL] [Abstract][Full Text] [Related]
35. [Omeprazole in the therapy of acid-induced diseases].
Simon B; Dammann HG; Müller P
Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
[TBL] [Abstract][Full Text] [Related]
36. Involvement of BCL-2 oncoprotein in the development of enterochromaffin-like cell gastric carcinoids.
Azzoni C; Doglioni C; Viale G; Delle Fave G; De Boni M; Caruana P; Ferraro G; Bordi C
Am J Surg Pathol; 1996 Apr; 20(4):433-41. PubMed ID: 8604810
[TBL] [Abstract][Full Text] [Related]
37. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.
Kuipers EJ; Nelis GF; Klinkenberg-Knol EC; Snel P; Goldfain D; Kolkman JJ; Festen HP; Dent J; Zeitoun P; Havu N; Lamm M; Walan A
Gut; 2004 Jan; 53(1):12-20. PubMed ID: 14684569
[TBL] [Abstract][Full Text] [Related]
38. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release.
Fykse V; Sandvik AK; Waldum HL
Scand J Gastroenterol; 2005 Nov; 40(11):1269-74. PubMed ID: 16334435
[TBL] [Abstract][Full Text] [Related]
39. Omeprazole and reflux oesophagitis.
Kerr GD
Aliment Pharmacol Ther; 1994 Apr; 8(2):263. PubMed ID: 8038359
[No Abstract] [Full Text] [Related]
40. Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls.
Diebold MD; Richardson S; Duchateau A; Bigard MA; Colin R; Cortot A; Fauchère JL; Zeitoun P
Dig Dis Sci; 1998 Aug; 43(8):1629-35. PubMed ID: 9724142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
